Cargando…

Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma

BACKGROUND: PD-L1 (programmed cell death 1 ligand 1) expression in melanoma has been associated with a better response to anti-PD-1 (programmed cell death 1) therapy. However, patients with PD-L1-negative melanomas can respond to anti-PD-1 blockade, suggesting that the other PD-1 ligand, PD-L2 (prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, Friederike, Zarbl, Romina, Niebel, Dennis, Sirokay, Judith, Fröhlich, Anne, Posch, Christian, Holderried, Tobias A. W., Brossart, Peter, Saavedra, Gonzalo, Kuster, Pia, Strieth, Sebastian, Gielen, Gerrit H., Ring, Sandra S., Dietrich, Jörn, Pietsch, Torsten, Flatz, Lukas, Kristiansen, Glen, Landsberg, Jennifer, Dietrich, Dimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318478/ https://www.ncbi.nlm.nih.gov/pubmed/32586358 http://dx.doi.org/10.1186/s13148-020-00883-9

Ejemplares similares

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
por: Niebel, Dennis, et al.
Publicado: (2022)

Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
por: Ralser, Damian J., et al.
Publicado: (2023)

Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors
por: Bao, Yilin, et al.
Publicado: (2021)

Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
por: Holderried, Tobias A. W., et al.
Publicado: (2019)

CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma
por: Hoffmann, Friederike, et al.
Publicado: (2023)

Nectin-4 is widely expressed in head and neck squamous cell carcinoma
por: Sanders, Christine, et al.
Publicado: (2022)

H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade
por: Hoffmann, Friederike, et al.
Publicado: (2020)

Clinical Management of Locally Advanced Basal-Cell Carcinomas and Future Therapeutic Directions
por: Niebel, Dennis, et al.
Publicado: (2020)

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
por: Franzen, Alina, et al.
Publicado: (2017)

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
por: Fröhlich, Anne, et al.
Publicado: (2020)

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
por: Fröhlich, Anne, et al.
Publicado: (2020)

DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
por: Sailer, Verena, et al.
Publicado: (2019)

PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients
por: Goltz, Diane, et al.
Publicado: (2017)

PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
por: Gevensleben, Heidrun, et al.
Publicado: (2016)

PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
por: Müller, Tim, et al.
Publicado: (2017)

Grzybowski’s Generalized Eruptive Keratoacanthomas in a Patient with Terminal Kidney Disease—An Unmet Medical Need Equally Ameliorated by Topical Imiquimod Cream and Lapacho Tea Wraps: A Case Report
por: Havenith, Regina, et al.
Publicado: (2021)

Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2017)

HGG-21. Oncogenic tyrosine kinase gene fusions in infant-type hemispheric gliomas - comparison of RNA- and DNA-based methods for their reliable detection
por: Pietsch, Torsten, et al.
Publicado: (2022)

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN
por: Pietsch, Torsten, et al.
Publicado: (2020)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites
por: Jung, Maria, et al.
Publicado: (2016)

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
por: Röver, Lea Kristin, et al.
Publicado: (2018)

PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2017)

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients
por: Goltz, Diane, et al.
Publicado: (2016)

PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy
por: Holmes, Emily Eva, et al.
Publicado: (2016)

Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study
por: Bergheim, Julia, et al.
Publicado: (2018)

Improved PCR Performance Using Template DNA from Formalin-Fixed and Paraffin-Embedded Tissues by Overcoming PCR Inhibition
por: Dietrich, Dimo, et al.
Publicado: (2013)

Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients
por: de Vos, Luka, et al.
Publicado: (2017)

PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2016)

FGFR-gerichtete Therapie von Kopf-Hals-Karzinomen
por: Dietrich, Dimo
Publicado: (2020)

The potential of eHealth for cancer patients–does COVID-19 pandemic change the attitude towards use of telemedicine services?
por: Holderried, Tobias A. W., et al.
Publicado: (2023)

Diagnostic and Prognostic Value of SHOX2 and SEPT9 DNA Methylation and Cytology in Benign, Paramalignant and Malignant Pleural Effusions
por: Dietrich, Dimo, et al.
Publicado: (2013)

Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma
por: Ellinger, Jörg, et al.
Publicado: (2016)

Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma
por: Brüggemann, Maria, et al.
Publicado: (2017)

TNF-α-Inhibition Improves the Biocompatibility of Porous Polyethylene Implants In Vivo
por: Hussain, Timon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bp8g7kbmvb2tocn24k2deraq5d